Baseline FGF23 is associated with cardiovascular outcome in incident PD patients

Peritoneal Dialysis International

Volumn 36, Issue 1, 2016, Pages 26-32

  Kim, Hyo Jin ^a   Park, Miseon ^a   Park, Hayne Cho ^a   Jeong, Jong Cheol ^a   Kim, Dong Ki ^a   Joo, Kwon Wook ^a   Hwang, Young Hwan ^b   Yang, Jaeseok ^a   Ahn, Curie ^a   Oh, Kook Hwan ^a  

^a Seoul National University Hospital   (South Korea)

^b Eulji General Hospital   (South Korea)

Author keywords

Cardiovascular disease; FGF23; Fibroblast growth factor 23; Peritoneal dialysis

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CALCIUM; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHORUS DERIVATIVE; FIBROBLAST GROWTH FACTOR;

ADULT; ARTERIAL STIFFNESS; ARTERY CALCIFICATION; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD ANALYSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; COMORBIDITY ASSESSMENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PULSE WAVE; RETROSPECTIVE STUDY; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 84957073497     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2013.00343     Document Type: Article

References (27)

1. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009; (114):S34–42.
2. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79:1370–8.
3. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432–9.
4. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22:1913–22.
5. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584–92.
6. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24:2792–6.
7. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152:640–8.
8. Arnlov J, Carlsson AC, Sundstrom J, Ingelsson E, Larsson A, Lind L, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013; 83:160–6.
9. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545–52.
10. Kirkpantur A, Balci M, Gurbuz OA, Afsar B, Canbakan B, Akdemir R, et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2011; 26:1346–54.
11. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16:489–95.
12. Garcia-Lopez E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 2007; 27(Suppl 2):S205–9.
13. Noordzij M, Cranenburg EM, Engelsman LF, Hermans MM, Boeschoten EW, Brandenburg VM, et al. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant 2011; 26:1662–9.
14. Sipahioglu MH, Kucuk H, Unal A, Kaya MG, Oguz F, Tokgoz B, et al. Impact of arterial stiffness on adverse cardiovascular outcomes and mortality in peritoneal dialysis patients. Perit Dial Int 2012; 32:73–80.
15. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99:2434–9.
16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450–8.
17. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 59:956–60.
18. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997; 132:245–50.
19. Symeonidis G, Papanas N, Giannakis I, Mavridis G, Lakasas G, Kyriakidis G, et al. Gravity of aortic arch calcification as evaluated in adult Greek patients. Int Angiol 2002; 21:233–6.
20. Baia LC, Humalda JK, Vervloet MG, Navis G, Bakker SJ, de Borst MH, et al. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013; 8:1968–78.
21. Westerberg PA, Tivesten A, Karlsson MK, Mellstrom D, Orwoll E, Ohlsson C, et al. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs). BMC Nephrol 2013; 14:85.
22. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006; 47:42–50.
23. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205:385–90.
24. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78:679–85.
25. Nakamura T, Saito Y, Ohyama Y, Masuda H, Sumino H, Kuro-o M, et al. Production of nitric oxide, but not prostacyclin, is reduced in klotho mice. Jpn J Pharmacol 2002; 89:149–56.
26. Silaruks S, Sirivongs D, Chunlertrith D. Left ventricular hypertrophy and clinical outcome in CAPD patients. Perit Dial Int 2000; 20:461–6.
27. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem 1997; 45:1005–19.